Explore Biospecimens from in.vent Diagnostica GmbH at Central BioHub

Central BioHub is proud to feature an extensive collection of high-quality biospecimens from in.vent Diagnostica GmbH, a premier Germany-based supplier known for its unwavering commitment to ethical practices and scientific rigor. Specializing in human serum, human plasma, urine, stool, and swabs, in.vent Diagnostica GmbH has been at the forefront of diagnostic research and development (R&D), fueling advances in autoimmune diseases, infectious diseases, and allergy research.

Advancing Diagnostic Research with Trusted Biospecimens

Biospecimens from in.vent Diagnostica GmbH undergo meticulous collection, processing, and characterization to ensure unmatched reliability for diagnostic R&D. Each sample complies with stringent ethical guidelines and comes with comprehensive documentation, enabling reproducible and impactful scientific discoveries.

Through its collaboration with in.vent Diagnostica GmbH, Central BioHub provides samples tailored for:

• Autoimmune Diseases: Leverage human serum and plasma samples tested for disease-specific biomarkers to support groundbreaking studies on conditions such as rheumatoid arthritis and lupus.
• Infectious Diseases: Advance the diagnosis of viral and bacterial infections with well-characterized stool and swab samples.
• Allergy Research: Access high-quality biospecimens designed to enhance understanding of allergen-specific immune responses.

Scientific Contributions

Biospecimens supplied by in.vent Diagnostica GmbH have been instrumental in pioneering research, as evidenced by:

• Detection of Reverse Transcriptase LAMP-Amplified Nucleic Acid from Oropharyngeal Viral Swab Samples Using Biotinylated DNA Probes through a Lateral Flow Assay
  This study focused on developing a rapid and reliable diagnostic method for detecting SARS-CoV-2 RNA using reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) combined with lateral flow assays. Positive and negative oropharyngeal viral swab samples, provided by in.vent Diagnostica GmbH, were employed as controls to validate the sensitivity and specificity of the assay. The findings demonstrated high diagnostic accuracy within a short timeframe, underscoring the potential of this method for point-of-care testing in low-resource settings.
• A Fluorometric Assay to Determine Labile Copper(II) Ions in Serum
  The aim of this research was to develop a high-throughput fluorometric assay to quantify labile copper ions in human serum, which are implicated in oxidative stress and diseases such as Wilson's disease. Standard serum samples provided by in.vent Diagnostica GmbH served as a reference to ensure the assay's accuracy and reproducibility. The study showed that the assay could detect labile copper ions with high sensitivity, making it a promising tool for routine clinical applications in diagnosing and monitoring copper-related conditions.
• Asymmetric Mach–Zehnder Interferometric Biosensing for Quantitative and Sensitive Multiplex Detection of Anti-SARS-CoV-2 Antibodies in Human Plasma
  This research explored the use of a cutting-edge biosensor platform, based on asymmetric Mach–Zehnder interferometry, to detect and quantify anti-SARS-CoV-2 antibodies. Plasma samples that were antibody-negative for SARS-CoV-2, supplied by in.vent Diagnostica GmbH, were used as controls to evaluate the biosensor's performance. The results highlighted the biosensor's high sensitivity and its ability to multiplex, allowing simultaneous detection of multiple antibody types. This innovation holds significant promise for serological testing and large-scale epidemiological studies during pandemics.
• Characterization of the Diagnostic Performance of a Novel COVID-19 PETIA in Comparison to Four Routine N-, S-, and RBD-Antigen Based Immunoassays
  This study assessed a new PETIA (particle-enhanced turbidimetric immunoassay) for COVID-19 diagnostics by comparing it to four established immunoassays targeting various SARS-CoV-2 antigens. A panel of serum samples from common coronaviruses, provided by in.vent Diagnostica GmbH, was used to evaluate the PETIA assay's cross-reactivity and specificity. The findings revealed that the PETIA assay performed on par with established methods, offering high sensitivity and specificity while showing minimal cross-reactivity, thus demonstrating its suitability for clinical diagnostics.

These studies highlight the critical role of biospecimens supplied by in.vent Diagnostica GmbH in advancing diagnostic research and innovation, particularly in the development of accurate and efficient tools for disease detection and monitoring.

The Central BioHub Difference

Central BioHub is the global leader in the online procurement of human biospecimens, streamlining access to ethically sourced, high-quality samples from trusted suppliers such as in.vent Diagnostica GmbH. With a user-friendly platform, cutting-edge search capabilities, and worldwide express shipping, Central BioHub is revolutionizing the way researchers procure biospecimens.

Explore Related Biospecimen Categories

Discover additional biospecimen categories tailored to your research needs:

• Healthy Donor Samples: Access control samples essential for baseline comparisons in diagnostic assays.
• Autoimmunity Samples: Browse a diverse range of human serum and plasma samples for autoimmune disease research.

Why Choose Central BioHub?

• Ethical Compliance: All suppliers uphold rigorous ethical and legal standards.
• Uncompromising Quality: Biospecimens are subject to stringent quality control processes.
• Simplified Procurement: Effortlessly search, filter, and order samples with global shipping options.
• Comprehensive Documentation: Gain access to detailed sample metadata, including donor demographics and clinical diagnostics.

Begin Your Journey Today

Whether driving innovation in autoimmune diseases, infectious diseases, or allergy research, Central BioHub and in.vent Diagnostica GmbH provide the resources to elevate your work. Start exploring our comprehensive inventory of ethically sourced, high-quality biospecimens today. Click here to explore now.

Together, we are shaping the future of diagnostic science and improving global healthcare outcomes.